FIELD: biotechnologies.
SUBSTANCE: peptide of the formula H-(N-Me)-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-D-Arg-Lys-NH2 is proposed. The proposed peptide may find application as an agent for reduction of pathological hyperpermeability of vessel endothelium in various areas of medicine (in cardiology, toxicology, neurosurgery, oncology, etc.).
EFFECT: prevention of sharp increase of vessel endothelium permeability when injected to a recipient.
3 cl, 4 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEOLYTICALLY STABLE NONAPEPTIDE CAPABLE OF PREVENTING AN INCREASE IN HYPERPERMEABILITY OF VASCULAR ENDOTHELIUM | 2018 |
|
RU2682878C1 |
| CYCLIC NONAPEPTIDE SHOWING ABILITY TO INHIBIT MYOSIN LIGHT CHAIN KINASE | 2010 |
|
RU2443710C1 |
| NONAPEPTIDE AMIDE, POSSESSING ABILITY TO PREVENT INCREASE OF VESSEL ENDOTHELIUM PERMEABILITY | 2009 |
|
RU2402565C1 |
| METHOD OF PRODUCING NONAPEPTIDES | 2015 |
|
RU2592282C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | 2016 |
|
RU2712623C2 |
| ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT | 2017 |
|
RU2762059C2 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| TREATING VASCULAR COMPLICATIONS OF DIABETES | 2010 |
|
RU2545718C2 |
| ACCELERATED HEALING OF EYE INJURIES BY ANGIOTENSIN PEPTIDES | 2014 |
|
RU2674148C2 |
